


Reminder: The outer packaging is for reference only, please purchase and use under the guidance of a pharmacist. For read by medical and pharmaceutical professionals only.
EMFLAZA is a prescription drug with the active ingredient deflazacort, a corticosteroid prodrug. It is marketed under the brand name EMFLAZA and is available in two primary dosage forms: immediate-release tablets and an oral suspension. The tablets come in four strengths (6 mg, 18 mg, 30 mg, and 36 mg), while the oral suspension has a concentration of 22.75 mg per mL. This medication is specifically developed for a chronic neuromuscular condition.
EMFLAZA is indicated for the treatment of Duchenne muscular dystrophy (DMD) in patients 2 years of age and older.
The recommended oral dosage is approximately 0.9 mg/kg once daily.
